Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
https://doi.org/10.17650/1818-8346-2011-6-2-8-11
Abstract
This article summarizes the results of 10 patients (6 men and 4 women) with recurrent non-Hodgkin lymphoma treating with using of rituximab. The diagnosis was confirmed by histological examination with immunohistochemistry. The average patient age was 61.1 years. All patients received from 6 to 8 chemotherapy courses and 8 rituximab injections, no one patient was withdrawn from therapy. Rituximab treatment in combination with chemotherapy was successful in 7 (70 %) of 10 patients. The major therapy response was a high frequency of CR — 40 %, slightly exceeding the rate of PR — 30 %. Rituximab has been used successfully in the treatment of elderly patients without additional toxicity, which makes it possible to use the drug on an outpatient basis.
About the Authors
R. A. Golubenko
Medical Institute of Orel State University
Orel regional hospital
Russian Federation
Russian Federation
Internal medicine department
G. B. Gromov
Medical Institute of Orel State University
Russian Federation
Surgery department
Russian Federation
Surgery department
V. I. Vishnevskiy
Medical Institute of Orel State University
Russian Federation
Internal medicine department
Russian Federation
Internal medicine department
References
1. Хансон К.П. , Имянитов Е.Н. Эпидемиология и биология неходжкинских лимфом. Практическая онкология 2004;5(3):163–8.
2. Swerdlow S.H., Campo E., Harris N.L. et al. World Health Organization Classification of Tumours of Hae matopoietic and Lymphoid Tissues. Lyon: IARC, 2008.
3. Поддубная И.В. Неходжкинские лимфомы. В кн.: Клиническая гематология: руководство для врачей. Под ред. М.А. Волковой. М: Медицина, 2001. С. 336–75.
4. Federico M., Bellei M., Marcheselli L. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognos tic factor project. J Clin Oncol 2009;27:4555–62.
5. Мазуров В.И. , Криволапов Ю.А. Классификация лимфом. Морфология, иммунофенотип, молекулярная генетика неходж кинских лимфом. Практическая онкология 2004;5(3):169–75.
6. Cheson B.D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:1–8.
7. Клинические рекомендации ESMO по диагностике, лечению и наблюдению при первично диагностированной крупноклеточной неходжкинской лимфоме. В кн.: Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). Ред. русского перевода проф. С.А. Тюляндин, проф. Н.И. Переводчикова, к.м.н. Д.А. Носов. М.: РОНЦ им. Н.Н. Блохина РАМН, 2009. С. 141–50.
8. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчиковой. Москва, 2005.
Review
For citations:
Golubenko R.A., Gromov G.B., Vishnevskiy V.I. Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region. Oncohematology. 2011;6(2):8-11. (In Russ.) https://doi.org/10.17650/1818-8346-2011-6-2-8-11
Views:
14392
Email this article 